Figure 2.

The identification of genes, pathways, and molecules relevant to pulmonary arterial hypertension (PAH) can be used for multiple purposes, including the improvement of clinical trial design. Subjects exposed to a given therapeutic could be compared in a number of different ways, including according to therapeutic response. Comprehensive approaches to explore the shared variations among those who respond and those who do not respond may support the determination of a predictive signature of response to help refine patient selection for a given therapeutic.